Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.975 USD | -3.80% | -7.38% | +31.82% |
Jun. 06 | Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024 | |
Jun. 06 | Addex Therapeutics' Q1 Net Loss Widens; Revenue Down | MT |
Sales 2024 * | 1.2M 1.34M | Sales 2025 * | 750K 838K | Capitalization | 5.92M 6.61M |
---|---|---|---|---|---|
Net income 2024 * | -4M -4.47M | Net income 2025 * | -3M -3.35M | EV / Sales 2024 * | 1.18 x |
Net cash position 2024 * | 4.5M 5.03M | Net Debt 2025 * | 710K 793K | EV / Sales 2025 * | 8.84 x |
P/E ratio 2024 * |
-2.01
x | P/E ratio 2025 * |
-2.41
x | Employees | 23 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.63% |
Latest transcript on Addex Therapeutics Ltd
1 day | -3.80% | ||
1 week | -7.38% | ||
Current month | -7.27% | ||
1 month | -9.58% | ||
3 months | -31.95% | ||
6 months | +46.33% | ||
Current year | +31.82% |
Managers | Title | Age | Since |
---|---|---|---|
Tim Dyer
FOU | Founder | 56 | 01-12-31 |
Lénaic Teyssédou
DFI | Director of Finance/CFO | 38 | 17-05-31 |
Vincent Lawton
CHM | Chairman | 75 | 09-04-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jake Nunn
BRD | Director/Board Member | 53 | 18-05-31 |
Tim Dyer
FOU | Founder | 56 | 01-12-31 |
Vincent Lawton
CHM | Chairman | 75 | 09-04-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-21 | 7.975 | -3.80% | 412 |
24-06-20 | 8.29 | +1.72% | 11,076 |
24-06-18 | 8.15 | +2.00% | 10,582 |
24-06-17 | 7.99 | -7.20% | 4,007 |
24-06-14 | 8.61 | -0.46% | 1,394 |
Delayed Quote Nasdaq, June 21, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- ADXN Stock
- ADXN Stock